Description

Retatrutide 10mg — Triple Receptor Agonist, Next-Generation Metabolic Research

Retatrutide is the most advanced metabolic research peptide available — and one of the most searched compounds in the peptide space right now. Developed by Eli Lilly, it’s currently in Phase III clinical trials and represents the next generation beyond semaglutide (Ozempic) and tirzepatide (Mounjaro) by targeting three receptors simultaneously: GLP-1, GIP, and glucagon.

The significance of the triple agonist approach is what makes retatrutide research so active. Semaglutide targets one receptor (GLP-1). Tirzepatide targets two (GLP-1 and GIP). Retatrutide targets all three — and Phase II clinical data published by Eli Lilly showed mean body weight reductions of up to 24% at 48 weeks, which is substantially higher than what was seen in equivalent semaglutide trials.

The compound’s pharmacokinetic profile — a roughly six-day half-life achieved through albumin-binding technology — supports once-weekly dosing in clinical research models. For researchers studying next-generation metabolic signaling, incretin hormone pathways, or comparative agonist activity, retatrutide is the leading-edge compound.

Best For: Metabolic; Body Composition

Category: Metabolic

For Research Use Only (RUO). Not for human or veterinary use. Not a drug. Not intended to diagnose, treat, cure, or prevent any disease.